Sunshine Heart appoints CRO for US clinical trial: Alquest, Inc.

Medical device company Sunshine Heart has contracted US research organisation Alquest to manage its North American clinical trial of the C-Pulse heart assist device.

Appointment of New Chief Financial Officer

Sunshine Heart, an ASX-listed medical device company, appoints Brian Bolton as its chief financial officer and company secretary from April 2007, thanking interim CFO Steven Skinner, ahead of United States clinical trials.

Peptech appoints global financial adviser to examine strategic options

Peptech's 2007 announcement of hiring Citigroup as adviser to weigh strategic options after takeover interest from private equity firms; discussions only, with no deal agreed.

Heart failure experts appointed as Co-Principal Investigators for Sunshine Heart's

Two American heart failure specialists have agreed to serve as co-principal investigators for Sunshine Heart's C-Pulse feasibility trial, which the company says adds credibility as it prepares a wider US study in 2007.

Peptech realises A$178m with Domantis sale completion

Peptech announces GSK has completed its buyout of Domantis, the UK biotech in which the Australian company held a stake, yielding it 71.3 million pounds and a large gain on its original investment.

Sunshine Heart on track for US trial following Pre-IDE Meeting with FDA

Device maker Sunshine Heart said its C-Pulse product moved closer to human trials in America after a positive regulator meeting, with a formal application planned for mid-2007 and hospitals already lined up.

$1.67 Million Grant To Develop Pain Drug

Spinifex Pharmaceuticals won a $1.67 million federal Commercial Ready grant to advance its neuropathic pain drug, after a $3.25 million syndicate raise the previous July; it was spun out of the University of Queensland.

Sunshine Heart receives positive progress reports from Product Development Partners

Sunshine Heart's US partners Plexus and Polymer Technology Group hit development milestones for the C-Pulse device ahead of a planned US clinical trial, with the company's operations chief praising the outsourced supplier model.

Sunshine Heart appoints leading US and Australian cardiologists to Medical Advisory Board

Heart device company Sunshine Heart added cardiologists Marc Silver and David Kaye to its medical advisory board in mid-2006, expanding a panel that guides work on its C-Pulse heart failure treatment.

Hatchtech wins Commercialisation Expo 2006 Prize for Best Australian Life Sciences Company

Melbourne biotech Hatchtech received two $10,000 Australian commercialisation prizes and had recently drawn down extra funding to sit alongside its $2.4 million government grant for its head lice treatment.

Crispin Marsh assumes non-executive role at Sunshine Heart

Sunshine Heart says co-founder Crispin Marsh will swap his executive corporate affairs role for a non-executive board seat from mid-2006, as the medical device maker brings in senior staff including a new COO.

Antipodean Pharmaceuticals Initiates Phase 2 Trial in Parkinsons's Disease Company's Lead Compound MitoQ Targets Mitochondrial Dysfunction

A 2006 announcement on venture firm GBS Ventures' site reports Antipodean Pharmaceuticals has begun a Phase 2 trial of its MitoQ compound targeting mitochondrial dysfunction in Parkinson's disease; details are in an attachment.

ASX / Media Announcement - Peptech acquires Promics and accelerates building product pipeline

Peptech's 2006 ASX announcement, reposted by GBS Ventures, reports its takeover of Promics; the page holds only a download link, with no price or further detail in the text.

Also GBS Ventures·GBS Ventures

FDA Approval for Portland Orthopaedics' Knee Replacement

Portland Orthopaedics wins US FDA approval for its Beacon Primary Knee, licensed from Signal Medical, and uses an AusIndustry grant to develop a revision knee product.

Proacta Inc Announces Phase I Clinical Trial of Novel Prodrug to Target Hypoxic Tumors

Biotech Proacta's release: its Phase I cancer-drug trial is underway, and Alta Partners' new funding tops the Series A up to $12M alongside lead backer GBS Ventures; Alta's David Mack joins the board.

OPAL Therapeutics Inc, Immunotherapy Start Up, Raises $US6m Series A to target HIV and Hepatitis C.

OPAL Therapeutics raised a US$6 million Series A, with GBS Venture Partners leading a syndicate including Alloy Ventures, Alta Partners and Uniseed, to develop HIV and hepatitis C immunotherapies from University of Melbourne technology.

CogState Accelerates Portfolio Development with A$1.28m Pfizer Deal

CogState has signed agreements giving it up to A$1.28 million in non-dilutive funding from Pfizer over three years for paediatric cognitive tests, speech-analysis technology and dementia detection tools, with work undertaken in Australia.

U.S. Phase III Aridol Trial Enrols First Patient

Pharmaxis announced its Aridol Phase III asthma diagnostic trial has enrolled first patients across 28 US sites, with FDA marketing authorisation planned for 2006.

Sunshine Heart Completes $3.3 million Capital Raising

Medical device firm Sunshine Heart closed a roughly A$3.3 million placement to institutional investors, funding its clinical trial and C-Pulse driver work; the release also cites an earlier A$2.2 million Commercial Ready grant.

Portland Orthopaedics Lists at 12% Premium

A 2005 GBS Ventures news post records Portland Orthopaedics' stock market debut at a 12% premium, with detail left to an attached document rather than given on the page itself.

Also GBS Ventures

Sunshine Heart ASX Release

A stub news page from GBS Ventures linking to an attached ASX release concerning Sunshine Heart, dated December 2005; the document's contents are not reproduced on the page.

Chief Operating Officer Appointed by Sunshine Heart

Sunshine Heart appoints Victor Windeyer as chief operating officer to lead its Australian operations and C-Pulse clinical trials from Sydney; the company also cites a secured grant and ethics approvals at two Melbourne hospitals.

Also GBS Ventures

Hip and Knee Replacements Company Portland Orthopaedics to Raise $5M in New IPO

A 2005 notice that Portland Orthopaedics, a Sydney hip and knee implant maker, planned a $5 million IPO, with a December ASX listing expected and Axis Financial Group brokering the offer.

PHARMAXIS LTD ANNOUNCES PRICING OF GLOBAL CAPITAL RAISING

Pharmaxis priced a two-tranche global capital raising: a US public offering plus an Australian institutional placement, with combined net proceeds around US$58.6 million (A$80 million) to fund drug development and manufacturing.

Sunshine Heart ASX Announcement

GBS Ventures' news page carries a brief entry linking to a downloadable Sunshine Heart ASX announcement, without describing what the announcement contains.

Sunshine Heart Appoints Clinical Affairs Manager

Medtech company Sunshine Heart has brought in Ruth Flynn as its first clinical affairs manager, to drive C-Pulse heart assist device trials across Australia and New Zealand from its Sydney head office.

Sunshine Heart Quarterly Investor Update October 2005

A stub page on GBS Ventures' site offering a downloadable Sunshine Heart investor update from October 2005; the page itself carries no content, figures, or transactions.

Pharmaxis Lists ADRs on NASDAQ

Australian drug developer Pharmaxis has won NASDAQ approval to trade its ADRs under ticker PXSLY, issuing no new shares; SEC registration is expected around 26 August 2005 before trading begins.

Also GBS Ventures·GBS Ventures

SPINIFEX SECURES $3.25 M INVESTMENT TO DEVELOP PAIN THERAPY

University of Queensland spinout Spinifex Pharmaceuticals landed $3.25 million from Symbiosis, GBS Venture Partners and Uniseed to advance its neuropathic pain therapy toward toxicology testing.

Also GBS Ventures·GBS Ventures·clinicalleader.com·bionity.com

Leading Australian Heart Surgeon Joins Sunshine Heart Inc Medical Advisory Board

ASX-listed medical device company Sunshine Heart appointed Melbourne heart transplant specialist Professor Don Esmore to its medical advisory board, which already includes academics from Penn State, Stanford and the Cleveland Clinic.

Study shows Promics' Second Generation Drug Active in Inflammatory Bowel Disease

News & Events

GBS Venture Partners closed its third life science fund at $145 million, exceeding its $120 million target, with backing from returning and new Australian institutional investors.

Patient in long term heart failure receives new hope through C-Pulse heart failure device

Surgeons in Auckland have placed the C-Pulse cardiac support device from Australian medtech Sunshine Heart into a patient for the first time, with further trial sites planned at Australian hospitals.

Sunshine Heart successful first implant of C-Pulse heart failure device

Sunshine Heart reported that surgeons at Auckland City Hospital implanted its C-Pulse heart device in a Class III heart failure patient, the procedure opening a trial of up to ten patients.

Cortical Pty Ltd Receives $3.03M START Grant

Melbourne drug-discovery firm Cortical has won an AusIndustry-administered federal R&D Start grant of $3.03 million, funding early clinical testing of its MIF-antagonist treatment candidate for inflammatory conditions.

Also GBS Ventures

HealthMatch - Changing the future of medicine. - Folklore

Folklore Ventures founder story recalling its seed backing of Manuri Gunawardena's clinical trial matching startup HealthMatch, plus follow-ons in its Series A and December 2020 Series B alongside Square Peg.

Perth’s Space Angel Awarded $1.75 Million To Progress WA’s First Spaceport

A Perth company received a government spaceport establishment grant to assess sites and develop a business case for Western Australia's first spaceport facility.

Transcelestial raises new funding

Transcelestial raised an undisclosed new round co-led by NTT Finance and Paspalis Capital, with several other investors participating, taking its total funding to USD 30.7 million as it expands laser communications in Japan and Australia.

Engage Squared secures funding to fuel AI growth across APAC

Microsoft partner Engage Squared has received investment from Alceon to build its AI, data and agent capabilities across APAC; the undisclosed sum is the first deal from Alceon's newly launched private equity fund.

Nexsen Limited IPO

Nexsen's investor page invites applications for its IPO under an August 2025 prospectus lodged with the corporate regulator; the share sale has not completed, so no funding is recorded.

Oneflare Pty. Acquires Urban You Pty - Mergr

M&A database entry recording Oneflare's 2018 acquisition of home services booking platform Urban You, its third Australian internet software deal, following its 2015 purchase of Word Of Mouth Online.

Full Interview: Hugging Face Co-Founder and CEO Clem Delangue

CBS News broadcasts Margaret Brennan's conversation with Hugging Face's co-founder and chief executive about a breach of the company's systems by an autonomous agent arising from an OpenAI-trained model.

Funding Bolsters BDM Team

Lender Funding has hired Lauren Severino and Sam Hermon as business development managers for New South Wales, expanding its BDM team to five amid growth in bridging and construction lending across the state.

Cadmus secures backing to safeguard university learning in the age of AI

The university assessment platform has raised new backing co-led by SEEK Investments and Glitch Capital, which it will use to enter the American market.

Hupo AI's $10M Series A Led by DST Global Partners

Sales-coaching AI startup Hupo has announced a $10 million Series A, with DST Global Partners leading and four earlier backers returning for the round.

One grain, many possibilities: unlocking the potential of Australian oats

FaBA profiles My PlantCo, Mei Yong's venture turning Australian oats into foods like Oat Rice, describing a $5.6 million FaBA project with GRDC co-investment now advancing the Real Oats range toward commercialisation.

Starward Whisky — Who Really Owns It? | Corporate Camouflage

A public-interest profile arguing Starward Whisky markets Melbourne independence while omitting its 2023 acquisition by UK multinational Diageo, with profits flowing overseas.

Balancing the Grind with RentBetter CEO, Jeremy Goldschmidt

RentBetter republishes a Balance the Grind interview in which founder and CEO Jeremy Goldschmidt describes his daily routine and mentions the proptech platform's recent funding round.

Justin Dry | Nurture Group

Nurture Her speaker page profiling Vinomofo's chief executive, covering the wine e-commerce firm's growth since 2011, overseas expansion, a US partnership and industry awards.

NFT firm Immutable valued at $2.5bn in Temasek-led financing

Sydney-based NFT gaming firm Immutable has secured $200 million in new backing spearheaded by Singapore's Temasek, valuing the company at $2.5 billion; Tencent, Mirae Asset, ParaFi Capital and Declaration Partners also joined.

Also cryptobriefing.com·checkcryptonews.com·TechCrunch Australia